Navigation Links
Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009
Date:12/7/2009

Senators Saxby Chambliss (R-GA) AND Johnny Isakson (R-GA) Join as Co-Sponsors

ATLANTA, Dec. 7 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance-Georgia (LCA-GA) acknowledged Senators Saxby Chambliss (R-GA) and Johnny Isakson (R-GA) for their leadership and support in establishing the first ever multi-agency, comprehensive program targeted at lung cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO)

Entitled Lung Cancer Mortality Reduction Act of 2009, S.332 authorizes a five year program to reduce the mortality rate of lung cancer which continues to be the number one cause of cancer deaths both nationally and in the state of Georgia. Lung cancer causes more deaths each year than breast, prostate, colon, kidney, melanoma and liver cancers combined.

"Lung cancer is the leading cause of cancer deaths among men and women. Anything that can be done to increase the parity in funding for this deadly disease will be a significant advance in reducing cancer morbidity and mortality," commented Senator Chambliss. "This legislation is a strong step in the right direction."

"We must make every effort to address lung cancer comprehensively and not overlook the import of earlier detection and better disease management," said Senator Isakson. "This is how we are going to make a difference in lung cancer mortality,"

In thanking the senators for their support, LCA-GA Chair and lung cancer survivor, Ed Levitt said, "Senators Chambliss and Isakson are looked to as leaders on cancer issues and their co-sponsorships of this breakthrough legislation is very significant. We sincerely thank them and look forward to working to continue to improve lung cancer outcomes in Georgia and beyond."

The bill requires the Secretaries of Health and Human Services, Defense and Veterans Affairs to combine forces on a comprehensive, coordinated plan of action with funding authorized for five years to accomplish the mortality reduction goal.

The National Cancer Institute (NCI) is required to review its funding priorities in order to meet the lung cancer mortality reduction goal and more national institutes are called on directly to take part, including the National Institute of Heart, Lung and Blood, the National Institute of Biomedical Imaging and Bioengineering and the National Institute for Environmental Health

To ensure accountability, the bill requires an annual report to Congress and creates an oversight board composed of the three Cabinet Secretaries and representatives from the fields of lung cancer treatment, research and advocacy.

In addition, the bill directs the Secretaries of Department of Defense (DOD) and Veterans' Affairs (VA) to implement an early detection and disease management program for military personnel who are at high risk for lung cancer because of smoking or exposure to carcinogens during active duty.

The bill also:

  • Authorizes the Food and Drug Administration (FDA) to create a new Lung Cancer Mortality Reduction drug program with incentives for new treatments, targeted therapies, vaccines and chemoprevention drugs for precancerous conditions.
  • Requires the Centers for Disease Control and Prevention to carry out an early disease research program targeted at the high incidence and mortality rates among minority and low-income populations.

The bill includes specific authorizations of $75,000,000 for certain NIH agencies in FY10 and authorizes such additional sums as may be necessary for all the cited agencies to accomplish the goal for FY 2010 through FY2014.

Lung Cancer Alliance (www.LungCancerAlliance.org) is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer. Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

CONTACT: Ed Levitt, elevitt@lungcanceralliance.org, 404-242-7414,

SOURCE Lung Cancer Alliance


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... sideline athletes. A type of groin injury, it occurs when the muscles around ... intense pain in and around the lower torso, as well as accompanying tenderness ...
(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a $2,500 Academic ... in a long time,” she said. , She thinks the coming week is going to ... thought I would have to help my students.” , The award will allow the 4th ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... sodium testing methods are complicated and require expert user knowledge. In a live ... method dedicated to the simplified, yet highly accurate, determination of sodium. , It ...
(Date:3/27/2017)... Orange, Texas (PRWEB) , ... March 27, 2017 ... ... celebration at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to ... giveaways and will be an opportunity for area-residents to celebrate two great years ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 On Friday, benchmark ... Composite closed the trading session up 0.19%; the Dow ... 500 was down 0.08%. US markets made broad based ... day in green. Pre-market today, Stock-Callers.com reviews these four ... (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. (NASDAQ: ... Paul M. Bisaro as Impax,s President and ... Board, effective March 27, 2017. Mr. Bisaro will succeed ... Interim President and Chief Executive Officer since December of ... and branded pharmaceutical experience, Mr. Bisaro, 56, is an ...
Breaking Medicine Technology: